Pharma Giants Compete: Novo Nordisk vs Eli Lilly
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Fool
- Market Share Competition: Novo Nordisk faces competition in the U.S. GLP-1 drug market from Eli Lilly, which currently holds a 60% market share, leading to a decline in Novo's market position and impacting its future revenue growth potential.
- Product Innovation and Sales: Novo's oral Wegovy drug has been approved and shows rapid market uptake, with initial data indicating that 36% of users are new to GLP-1 drugs, potentially expanding the patient base and enhancing the company's competitiveness in the fast-growing weight loss drug market.
- Eli Lilly's Strong Performance: Eli Lilly achieved over $36 billion in revenue last year through Mounjaro and Zepbound, demonstrating robust growth in the weight loss drug market, and its newly approved oral drug Foundayo may further strengthen its market position.
- Investment and Future Outlook: While Novo's lower valuation may attract investors, Eli Lilly's strong performance in the oral GLP-1 market and the launch of new products could give it an edge in future market competition, affecting Novo's growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 953.300
Low
950.00
Averages
1192
High
1500
Current: 953.300
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Foundayo Receives FDA Approval and Launches Nationwide
- Drug Launch: Eli Lilly announced that its weight loss medication Foundayo™ (orforglipron) received FDA approval on April 1, 2026, and became available through LillyDirect® and telehealth providers on April 9, marking a significant advancement in the weight loss market.
- Pricing and Accessibility: Foundayo is priced at $149 per month for self-pay patients, while eligible commercially insured patients can pay as little as $25 per month with a savings card, demonstrating Lilly's commitment to reducing patient burden and expanding drug accessibility.
- Clinical Trial Results: In the ATTAIN-1 clinical trial, patients on the highest dose lost an average of 27.3 pounds (12.4%), compared to only 2.2 pounds (0.9%) in the placebo group, indicating a significant advantage in weight loss efficacy that could enhance market acceptance.
- Health Risks and Side Effects: Foundayo may cause serious side effects, including thyroid tumors, requiring patients to be vigilant for symptoms; nevertheless, the drug's effectiveness and convenience continue to attract many seeking weight loss solutions.
See More
URTH ETF 52-Week Price Analysis
- Price Range Analysis: URTH ETF's 52-week low is $140.22 per share, with a high of $192.84, and the latest trade at $186.76 indicates stability near the high, potentially attracting investor interest in price fluctuations.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable technical insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights those experiencing significant inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets and market sentiment.
See More
Intensifying Competition in India's Weight-Loss Drug Market
- Market Share Shift: According to Pharmarack data, Eli Lilly's market share in India's GLP-1 weight-loss drug sector fell from 61% in March to 56%, while rival Novo Nordisk maintained a steady 25%, indicating fierce market competition.
- Patent Expiry Impact: The expiration of semaglutide's patent has led 13 Indian generic companies to launch 26 new brands rapidly, resulting in a more significant sales hit for Eli Lilly, with experts predicting further erosion for its tirzepatide-based products.
- Escalating Price Wars: In addition to launching cheaper generics, Novo Nordisk has reduced prices for its Ozempic and Wegovy by 38% and 48%, respectively, aiming to maintain competitiveness in the Indian market and further narrowing the price gap with generics.
- Optimistic Market Outlook: The Indian GLP-1 market is expected to grow nearly five-fold to 50 billion rupees by 2030, with some bullish estimates exceeding $1.2 billion, reflecting strong demand for weight-loss and diabetes medications.
See More
U.S. Stocks Rally as Market Sentiment Improves
- Strong Market Performance: The S&P 500 has risen 3.7% since Monday, marking a seven-day winning streak, the longest since October, indicating a significant improvement in market sentiment and a rebound in investor confidence.
- Inflation Data Expectations: Economists anticipate that the consumer price index, set to be released on Friday, will show a 3.3% year-over-year increase, with a 2.7% rise excluding food and energy, which could significantly impact market sentiment and investment decisions amid rising oil prices.
- Tech Sector Volatility: The iShares Expanded Tech-Software Sector ETF (IGV) fell about 4%, hitting a 52-week low, primarily due to the rollout of Anthropic's latest platform, highlighting the fragility of tech stocks and potentially affecting investor confidence in the sector.
- Amazon's AI Investment: Amazon's stock surged 5.6%, its largest gain since October, as CEO Andy Jassy announced plans to invest approximately $200 billion in AI infrastructure, underscoring the company's commitment to future technological advancements and its competitive position in the market.
See More
Foundayo Now Available in US for Weight Loss
- Drug Launch: Eli Lilly announced that its weight loss medication Foundayo™ (orforglipron) received FDA approval on April 1, 2026, and is now available at retail pharmacies and through LillyDirect®, marking a significant expansion in the weight loss drug market.
- Pricing Strategy: Foundayo is priced at $25 per month for patients with commercial insurance and $149 for self-pay patients, a strategy designed to enhance accessibility and attract a large patient base in need of weight loss solutions.
- Clinical Efficacy: In the ATTAIN clinical trials, patients using Foundayo lost an average of 27.3 pounds (12.4%), significantly outperforming the placebo group, which lost only 2.2 pounds (0.9%), demonstrating the drug's effectiveness and potentially boosting the company's competitive edge in the weight loss market.
- Market Outlook: With approximately half of employer-sponsored health plans in the U.S. lacking coverage for weight loss medications, Lilly's introduction of various payment options reflects its commitment to expanding market share, likely enhancing brand influence and market penetration.
See More
Healthcare Stocks Mixed as NYSE Health Care Index Edges Up 0.1%
- Mixed Market Performance: Late Thursday afternoon, healthcare stocks showed mixed results, with the NYSE Health Care Index rising by 0.1%, indicating a cautious market sentiment towards the healthcare sector amid economic uncertainties.
- Investor Sentiment Fluctuations: While the overall index saw a slight increase, individual healthcare stocks exhibited varied performances, influenced by company earnings reports and market dynamics, highlighting the volatility and uncertainty in investor sentiment.
- Uncertain Industry Outlook: The future of the healthcare industry faces challenges, particularly in light of changing policies and economic conditions, prompting investors to closely monitor potential impacts from regulatory changes on the sector.
- Long-Term Trends to Watch: Despite the mixed short-term performance of healthcare stocks, the sector is still viewed as having growth potential in the long run, driven by an aging population and increasing health demands.
See More
Foundayo Receives FDA Approval and Launches Nationwide
- Drug Launch: Eli Lilly announced that its weight loss medication Foundayo™ (orforglipron) received FDA approval on April 1, 2026, and became available through LillyDirect® and telehealth providers on April 9, marking a significant advancement in the weight loss market.
- Pricing and Accessibility: Foundayo is priced at $149 per month for self-pay patients, while eligible commercially insured patients can pay as little as $25 per month with a savings card, demonstrating Lilly's commitment to reducing patient burden and expanding drug accessibility.
- Clinical Trial Results: In the ATTAIN-1 clinical trial, patients on the highest dose lost an average of 27.3 pounds (12.4%), compared to only 2.2 pounds (0.9%) in the placebo group, indicating a significant advantage in weight loss efficacy that could enhance market acceptance.
- Health Risks and Side Effects: Foundayo may cause serious side effects, including thyroid tumors, requiring patients to be vigilant for symptoms; nevertheless, the drug's effectiveness and convenience continue to attract many seeking weight loss solutions.
See More
URTH ETF 52-Week Price Analysis
- Price Range Analysis: URTH ETF's 52-week low is $140.22 per share, with a high of $192.84, and the latest trade at $186.76 indicates stability near the high, potentially attracting investor interest in price fluctuations.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable technical insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights those experiencing significant inflows (new units created) or outflows (old units destroyed), allowing assessment of their impact on underlying assets and market sentiment.
See More
Intensifying Competition in India's Weight-Loss Drug Market
- Market Share Shift: According to Pharmarack data, Eli Lilly's market share in India's GLP-1 weight-loss drug sector fell from 61% in March to 56%, while rival Novo Nordisk maintained a steady 25%, indicating fierce market competition.
- Patent Expiry Impact: The expiration of semaglutide's patent has led 13 Indian generic companies to launch 26 new brands rapidly, resulting in a more significant sales hit for Eli Lilly, with experts predicting further erosion for its tirzepatide-based products.
- Escalating Price Wars: In addition to launching cheaper generics, Novo Nordisk has reduced prices for its Ozempic and Wegovy by 38% and 48%, respectively, aiming to maintain competitiveness in the Indian market and further narrowing the price gap with generics.
- Optimistic Market Outlook: The Indian GLP-1 market is expected to grow nearly five-fold to 50 billion rupees by 2030, with some bullish estimates exceeding $1.2 billion, reflecting strong demand for weight-loss and diabetes medications.
See More
U.S. Stocks Rally as Market Sentiment Improves
- Strong Market Performance: The S&P 500 has risen 3.7% since Monday, marking a seven-day winning streak, the longest since October, indicating a significant improvement in market sentiment and a rebound in investor confidence.
- Inflation Data Expectations: Economists anticipate that the consumer price index, set to be released on Friday, will show a 3.3% year-over-year increase, with a 2.7% rise excluding food and energy, which could significantly impact market sentiment and investment decisions amid rising oil prices.
- Tech Sector Volatility: The iShares Expanded Tech-Software Sector ETF (IGV) fell about 4%, hitting a 52-week low, primarily due to the rollout of Anthropic's latest platform, highlighting the fragility of tech stocks and potentially affecting investor confidence in the sector.
- Amazon's AI Investment: Amazon's stock surged 5.6%, its largest gain since October, as CEO Andy Jassy announced plans to invest approximately $200 billion in AI infrastructure, underscoring the company's commitment to future technological advancements and its competitive position in the market.
See More
Foundayo Now Available in US for Weight Loss
- Drug Launch: Eli Lilly announced that its weight loss medication Foundayo™ (orforglipron) received FDA approval on April 1, 2026, and is now available at retail pharmacies and through LillyDirect®, marking a significant expansion in the weight loss drug market.
- Pricing Strategy: Foundayo is priced at $25 per month for patients with commercial insurance and $149 for self-pay patients, a strategy designed to enhance accessibility and attract a large patient base in need of weight loss solutions.
- Clinical Efficacy: In the ATTAIN clinical trials, patients using Foundayo lost an average of 27.3 pounds (12.4%), significantly outperforming the placebo group, which lost only 2.2 pounds (0.9%), demonstrating the drug's effectiveness and potentially boosting the company's competitive edge in the weight loss market.
- Market Outlook: With approximately half of employer-sponsored health plans in the U.S. lacking coverage for weight loss medications, Lilly's introduction of various payment options reflects its commitment to expanding market share, likely enhancing brand influence and market penetration.
See More
Healthcare Stocks Mixed as NYSE Health Care Index Edges Up 0.1%
- Mixed Market Performance: Late Thursday afternoon, healthcare stocks showed mixed results, with the NYSE Health Care Index rising by 0.1%, indicating a cautious market sentiment towards the healthcare sector amid economic uncertainties.
- Investor Sentiment Fluctuations: While the overall index saw a slight increase, individual healthcare stocks exhibited varied performances, influenced by company earnings reports and market dynamics, highlighting the volatility and uncertainty in investor sentiment.
- Uncertain Industry Outlook: The future of the healthcare industry faces challenges, particularly in light of changing policies and economic conditions, prompting investors to closely monitor potential impacts from regulatory changes on the sector.
- Long-Term Trends to Watch: Despite the mixed short-term performance of healthcare stocks, the sector is still viewed as having growth potential in the long run, driven by an aging population and increasing health demands.
See More
